OncoAlert and ecancer ASCO roundup - Day 3

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

OncoAlert and ecancer ASCO roundup - Day 2

OncoAlert and ecancer ASCO roundup - Day 1

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma